Your cart is currently empty!
Category: Osteoporosis
Denosumab
Description
This page contains brief details about the drug denosumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The U.S. FDA approved Denosumab for the first time on June 1, 2010, to treat postmenopausal women with osteoporosis at high risk for fracture.
Mechanism of Action of Denosumab
Osteoclast breaks the tissues in the bones and releases calcium into the blood. This process is called bone resorption. Denosumab acts by inhibiting osteoclast formation, thereby decreasing bone resorption and increasing bone mass and strength.
Uses of Denosumab
Osteoporosis in women postmenopause who are at high risk of fracture
Men with osteoporosis who are at increased risk of fracture
Bone loss in men due to reduced levels of testosterone caused as a result of prostate cancer surgery or treatment with medications
Osteoporosis in patients with a high risk of fracture due to long-term treatment with glucocorticoids.
And increase bone mass in women at high risk of fracture due to adjuvant aromatase inhibitor therapy for breast cancer.
Denosumab Dosage available
Denosumab is to be administered by a healthcare provider. It is injected subcutaneously under the skin of stomach, upper thigh or upper arm. Denosumab is to be given once every six months.
Pamidronate
Description
This page contains brief details about the drug pamidronate, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Pamidronate consists of the active substance Pamidronate. It is a medication that belongs to a class of drugs called bisphosphonates. It is used to treat high calcium levels in the blood, a condition known as hypercalcemia, which can be caused by cancer or other medical conditions. This helps to increase bone density and reduce the risk of fractures in people with osteoporosis (bone weakening) or other bone conditions. It works by slowing down the breakdown of bone tissue, which helps reduce the amount of calcium released into the bloodstream. The dosage and frequency of administration will depend on the individual’s medical condition and other factors such as age, weight, and overall health.
Pamidronate was first approved by the U.S. Food and Drug Administration (FDA) in 1991 for treating hypercalcemia of malignancy, a condition in which cancer cells release calcium into the bloodstream. Since then, pamidronate has also been approved for treating other conditions related to bone metabolisms, such as osteoporosis and Paget’s disease of bone.
Mechanism of Action of Pamidronate
Pamidronate belongs to a class of drugs called bisphosphonates, which inhibit the activity of osteoclasts. Osteoclasts are responsible for breaking down bone tissue, which releases calcium into the bloodstream. By inhibiting osteoclasts’ activity, it helps slow down the breakdown of bone tissue and reduce the amount of calcium released into the bloodstream.
Uses of Pamidronate
Pamidronate is a medication used to treat various bone-related conditions, including hypercalcemia, cancer-related bone diseases, osteoporosis, and Paget’s disease of bone. It is also used in treatment of breast cancer metastasis (spread) to bone and osteolytic lesion of multiple myeloma (a type of bone cancer).
Ibandronate Sodium Monohydrate
Anti-osteoporosis